Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

New England Journal of Medicine

Volumn 339, Issue 1, 1998, Pages 21-26

  Miller, Thomas P ^a,e   Dahlberg, Steve ^b   Cassady, J Robert ^a   Adelstein, David J ^c   Spier, Catherine M ^a   Grogan, Thomas M ^a   LeBlanc, Michael ^b   Carlin, Susan ^b   Chase, Ellen ^a   Fisher, Richard I ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b Statistical Center   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^e Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; DIAGNOSTIC APPROACH ROUTE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0032474694     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199807023390104     Document Type: Article

References (25)

1. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
3. Jones SE, Miller TP, Connors JM. Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989;7:1186-91.
4. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023-30.
5. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and descripiton of a working formulation for clinical usage. Cancer 1982;49:2112-35.
6. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
8. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
9. Cox DR. Regression models and life-tables. JR Stat Soc [B] 1972;34: 187-202.
10. Kaminski MS, Coleman CN, Colby TV, Cox RS, Rosenberg SA. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986;104:747-56.
11. Landberg TG, Hakansson LG, Moller TR, et al. CVP-remission maintenance in stage I or II non-Hodgkin's lymphomas: preliminary results of a randomized study. Cancer 1979;44:831-8.
12. Levitt SH, Bloomfield CD, Frizzera G, Lee CK. Curative radiotherapy for localized diffuse histiocytic lymphoma. Cancer Treat Rep 1980;64:175-7.
13. Sweet DL, Kinzie J, Gaeke ME, Golomb HM, Ferguson DL, Ultmann JE. Survival of patients with localized diffuse histiocytic lymphoma. Blood 1981;58:1218-23.
14. Bonadonna G, Bajetta E, Lattuada A, et al. CVP versus BACOP chemotherapy sequentially combined with irradiation in stage I-II diffuse non-Hodgkin's lymphomas. In: Jones SE, Salmon SE, eds. Adjuvant therapy of cancer IV. Orlando, Fla.: Grune & Stratton, 1984:661-8.
15. Nissen NI, Ersboll J, Hansen HS, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983;52:1-7.
16. Miller TP, Jones SE. Chemotherapy of localised histiocytic lymphoma. Lancet 1979;1:358-60.
17. Cabanillas F, Bodey GP, Freireich EJ. Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 1980;46:2356-9.
18. Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Intern Med 1987;107:25-30.
19. Longo DL, Glatstein E, Duffey PL, et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 1989;7:1295-302.
20. Miller TP, Jones SE. Initial chemotherapy for clinically localized lymphomas of unfavorable histology. Blood 1983;62:413-8.
21. Idem. Is there a role for radiotherapy in localized diffuse lymphomas? Cancer Chemother Pharmacol 1980;4:67-70.
22. Glick JH, Kim K, Earl J. An ECOG randomized phase III trial of CHOP vs CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1995;14:391. abstract.
23. Abrahamsen JF, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol 1993;11:255-61.
24. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312-25.
25. Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993;85: 1932-7.